First AD

Second AD

Michael A. Postow, MD, is chief of the Melanoma Service and co-director of the Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Center in New York, New York.

Chenyang Zhan, MD, PhD, is an interventional radiologist at Memorial Sloan Kettering Cancer Center in New York, New York.

Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.

The Promise of Oncolytic Viruses in Advanced Melanoma

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Melanoma & Skin Cancer

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Data for RP1 Plus Nivolumab in Metastatic Melanoma After Prior PD-1 Inhibition